IRIS
ZANARDI, ELISA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 6.595
AS - Asia 11
SA - Sud America 2
NA - Nord America 1
Totale 6.609
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 6.595
CN - Cina 9
BR - Brasile 2
SG - Singapore 2
US - Stati Uniti d'America 1
Totale 6.609
Salva come PNG Salva come JPEG
Città #
Genova 3.352
Genoa 2.018
Rapallo 682
Vado Ligure 535
Bordighera 8
Beijing 3
Singapore 2
Aparecida de Goiânia 1
Ashburn 1
Recife 1
Totale 6.603
Salva come PNG Salva come JPEG
Nome #
Overexpression of Periostin in Tumor Biopsy Samples Is Associated With Prostate Cancer Phenotype and Clinical Outcome 222
Impaired response to influenza vaccine associated with persistent memory B cell depletion in non-Hodgkin's lymphoma patients treated with rituximab-containing regimens. 187
A Case of Plasmacytoid Variant of Bladder Cancer with a Single Penile Metastasis and a Complete Response to Carboplatin-Based Chemotherapy and Review of the Literature 173
Prospective study to optimize care and improve knowledge on ovarian function and/or fertility preservation in young breast cancer patients: Results of the pilot phase of the PREgnancy and FERtility (PREFER) study 166
Androgen-deprivation therapy is more than palliation in oligometastatic prostate cancer 166
CDK4/6 inhibitors in advanced hormone receptor-positive/HER2-negative breast cancer: a systematic review and meta-analysis of randomized trials 161
Prognostic variables in localized small cell neuroendocrine carcinoma of the bladder: A population-based study 160
Abiraterone acetate and prednisone in the pre- and post-docetaxel setting for metastatic castration-resistant prostate cancer: A mono-institutional experience focused on cardiovascular events and their impact on clinical outcomes 154
Prognostic value of preoperative serum levels of periostin (PN) in early breast cancer (BCa) 154
Current Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer 150
Seasonal and pandemic (A/H1N1 2009) MF-59-adjuvanted influenza vaccines in complete remission non-Hodgkin lymphoma patients previously treated with rituximab containing regimens. 146
Cisplatin (C)-paclitaxel (P) chemotherapy (CT) regimen with concurrent radiotherapy (RT) in local advanced (LACC) or recurrent (LRCC) cervical cancer: 14 year-results of a phase II study 146
Better Together: Targeted Combination Therapies in Breast Cancer 143
Combinations of hormonal therapy and chemotherapy 142
Targeting androgen-independent pathways: new chances for patients with prostate cancer? 142
Concurrent vs Sequential Adjuvant Chemotherapy and Hormone Therapy in Breast Cancer: A Multicenter Randomized Phase III Trial 140
Bone metastases from prostate cancer: hormonal therapy 138
Clinical experience with temsirolimus in the treatment of advanced renal cell carcinoma 136
May adjuvant therapy play a role for the management of renal cell carcinoma? A review of literature and ongoing trials 135
Relevance of HBV/HBcAb screening in lymphoma patients treated in the Rituximab era 131
Role of Circulating Tumor Cells (CTC), Androgen Receptor Full Length (AR-FL) and Androgen Receptor Splice Variant 7 (AR-V7) in a Prospective Cohort of Castration-Resistant Metastatic Prostate Cancer Patients 130
Adjuvant Carboplatin Treatment in 115 Patients With Stage I Seminoma: Retrospective Multicenter Survey 129
Patients Treated with Rituximab-Containing Immunochemotherapy Have a Significant and Prolonged Lack of Humoral Response to Influenza Vaccine Associated with a Persistent Depletion of B Memory Cells 127
Impact of body mass index on the clinical outcomes of patients with HER2-positive metastatic breast cancer 127
Cardiovascular disease (CVD) markers in patients(pts) with prostate cancer(PCa) treated with GN-RH agonists(AG) or antagonist(AN): a prospective cohort study 122
Patterns of care and clinical outcomes of first-line trastuzumab-based therapy in HER2-positive metastatic breast cancer patients relapsing after (Neo)adjuvant trastuzumab: An Italian multicenter retrospective cohort study 121
Treatment of elderly patients with metastatic renal cell carcinoma 118
Prognostic Variables in Patients With Non-metastatic Small-cell Neuroendocrine Carcinoma of the Bladder: A Population-Based Study 118
A large SEER- based study of survival trends in patients with de novo metastatic prostate cancer 118
Role of Baseline and Post-Therapy 18F-FDG PET in the Prognostic Stratification of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated with Radium-223 116
To switch or not to switch? A real-life experience using dexamethasone in combination with abiraterone 113
Abiraterone acetate (AA) in pre- and post-docetaxel (DX) setting for metastatic castration resistant prostate cancer (mCRPC): a monoinstitutional experience focused on cardiovascular events and on their impact on clinical outcomes 112
861P Time to castration resistant prostate cancer (CRPC) and the risk of developing immune disorders 108
Reduced dose of cabazitaxel in metastatic castration-resistant prostate cancer: from PROSELICA trial to the real life: A single institution experience 103
EFFICACY AND SAFETY OF SUNITINIB AND EVEROLIMUS AS FRONTLINE TREATMENT FOR NON-CC-RCC: A POOLED-ANALYSIS FROM RANDOMIZED TRIALS 101
Better Together: Immunotherapy as Future Combination Strategy for Breast Cancer 100
Insights from a long-term follow-up evaluation of early breast cancer (BC) outcomes by tumor subtype (TS) 97
Risks and benefits from CDK inhibitors for advanced HR+ Her 2- breast cancer 97
First line trastuzumab- or lapatinib-based therapy in her2-positive metastatic breast cancer patients after prior (NEO) adjuvant trastuzumab 96
Advanced soft-tissue sarcoma in elderly patients: patterns of care and survival 94
First line trastuzumab-based therapy in HER2-positive metastatic breast cancer patients (MBC) presenting with de novo or recurrent disease 93
Telomerase-based GX301 cancer vaccine in patients with metastatic castration-resistant prostate cancer: a randomized phase II trial 90
Baseline 18F-Fluoride PET-derived parameters predict modification of toxicity-and response-related blood biomarkers in prostate cancer patients treated with 223Ra-Dichloride: preliminary results 89
BRCA Mutations in Prostate Cancer: Prognostic and Predictive Implications 89
Dose calculation and tolerability of adjuvant AUC 7 carboplatin in 100 patients with stage I seminoma 87
Integrative Analysis of Periostin in Primary and Advanced Prostate Cancer 83
Combination therapy in metastatic renal cell carcinoma: Back to the future? 81
Response to trabectedin in a patient with advanced synovial sarcoma with lung metastases 79
HER2-Positive Neuroendocrine Breast Cancer: Case Report and Review of Literature 78
Management of advanced endometrial cancer 78
Beyond the Prognostic Value of 2-[18F]FDG PET/CT in Prostate Cancer: A Case Series and Literature Review Focusing on the Diagnostic Value and Impact on Patient Management 76
Opportunistic skeletal muscle metrics as prognostic tools in metastatic castration-resistant prostate cancer patients candidates to receive Radium-223 75
Long-term results from INT-HER study: Retrospective evaluation of adjuvant trastuzumab in unselected HER2-positive breast cancer patients—Single institution experience 73
Real-world survival improvements in patients with newly diagnosed metastatic prostate cancer treated in the United States 70
Immune Checkpoint Inhibitors in Advanced Prostate Cancer: Current Data and Future Perspectives 61
Case report: Pembrolizumab plus Axitinib related hypothyroid myopathy in two kidney cancer patients 54
Cardiac Metastasis from Prostate Cancer: A Case Study Underlying the Crucial Role of the PSMA PET/CT 52
SUNITINIB IN METASTATIC RENAL CELL CARCINOMA: RESULTS OF A MONOCENTRIC EXPERIENCE 42
Neoplasie prostatiche 41
Role of FDG PET/CT in the prognostic stratification and response assessment of castration-resistant prostate cancer treated with radium-223 dichloride 41
null 40
Totale 6.811
Salva come PNG Salva come JPEG
Categoria #
all - tutte 25.061
article - articoli 23.322
book - libri 0
conference - conferenze 397
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 1.342
Totale 50.122
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021462 0 0 0 74 55 46 17 59 29 80 48 54
2021/2022713 23 24 39 75 29 73 15 147 75 76 43 94
2022/2023778 58 82 11 77 141 128 0 64 122 5 80 10
2023/2024450 12 57 11 57 28 85 24 27 22 27 30 70
2024/20251.423 36 87 45 110 158 148 124 297 38 65 144 171
2025/2026618 299 73 137 109 0 0 0 0 0 0 0 0
Totale 6.811